The Three Things VCs Are Really De‑Risking
Strip away the jargon and the models, and early‑stage platform biotech investing usually comes down to three questions.
1. Can this team build a real platform?
Not a single assay, not a one‑off AI model, not a beautiful lab—but a repeatable engine that:
Generates high‑quality data at scale
Gets better (cheaper, faster, smarter) as it runs
Spits out programs, products, or deals on purpose, not by accident
Signals VCs look for:
Someone clearly “owns” the platform (not a vague committee)
Early data is organised, annotated, and already feeding back into design
There’s a concrete roadmap for how the platform deepens over 12–24 months
2. Will they pick the right first program(s)?
A platform is only as believable as the first programs it produces.
Investors are asking:
Are you picking programs that show off the platform’s unique edge?
Are they scoped to hit tractable, time‑bound milestones (not “come back in 5 years”)?
Do they translate into clear value‑inflection points for the next round or a partnership?
Signals VCs look for:
A rational “why this indication/target/modality first?” story
Explicit trade‑offs you’ve made (and can explain)
A development plan that’s been pressure‑tested by someone who has actually taken something through a regulated path
3. Can they raise the next round and attract partners?
The science can be great and the platform real—but if you can’t:
Tell the story
Run a disciplined fundraising and BD process
Keep the company capital‑efficient and focused
…you run out of runway before the engine ever turns over.
Signals VCs look for:
Someone on the team who can own narrative, process, and relationships
A credible 18–24‑month plan: what gets done on this capital, and who needs to be in seat to do it
Evidence that you understand partner needs and diligence expectations
This was explored in "Can this founder Scale? A Partner's checklist for Life Sciences VCs"
How Each of the First Five Roles Maps to What VCs Want to See
An earlier blog "The first 5 Hires for a Platform Biotech: Who, When and Why?" Laid out the five foundational roles for a platform biotech:
Platform Architect
“Glue” Operator
Biology ↔ Data / Platform Infrastructure Lead
Early Regulatory / Quality Voice
Business / Fundraising Partner
Below, for each role:
What a VC wants to hear/see
What worries them (signals you’re missing that archetype)
Use this as a mirror: if you don’t have all five fully in‑house yet, you can still show you understand the archetypes and have a plan to cover them.
1. Platform Architect
What VCs want to see
A clearly identifiable person who owns the platform concept end‑to‑end
Ability to explain the architecture simply: inputs → core engine → outputs
Evidence of hard trade‑offs already made:
“We didn’t build these assays/models because…”
“We standardised on X even though Y is sexier because…”
A sharp view of what “platform working” means in 12–18 months (3–5 concrete proof points)
What worries them
Multiple founders all vaguely “own” the science, no one owns the platform
Hand‑wavy claims about scalability or AI with no concrete plan for data, throughput, or automation
Early work looks like a series of bespoke experiments, not a converging workflow
The Architect cannot clearly articulate kill‑criteria or prioritisation logic
2. The “Glue” Operator (Head of Ops / Chief of Staff)
What VCs want to see
Someone who obviously runs the machine of the company:
Lab setup, vendors, purchasing, basic HR/finance, project coordination
Clear, pragmatic plans for Lab 1.0:
Where you’ll be, what equipment you’ll have, in which order, at what cost
Evidence of discipline:
A simple milestone and runway plan
Awareness of burn, hiring pacing, and operational risk
Founders who are not spending their time chasing vendors and assembling freezers
What worries them
Brilliant science team, but nobody who seems to “own” execution
Vague answers on practicalities: where are you setting up, when, with what budget?
Founders proudly doing all the ops themselves (“we’re scrappy!”) with no plan to offload
No single point of accountability for timelines, burn, and milestone tracking
3. Biology ↔ Data / Platform Infrastructure Lead
What VCs want to see
A specific person at the bench–data interface (even if fractional initially)
Early evidence of structured data thinking:
Standardised file naming, metadata, QC criteria
Basic pipelines for analysis and visualisation
A roadmap for how the platform’s data asset compounds over time:
What gets logged
How it feeds back into design
How it becomes a defensible moat
For AI/ML narratives: realistic expectations about when models will be truly predictive and how they’ll be validated experimentally
What worries them
“We’ll just hire a data person later” for a fundamentally data‑driven platform
Data spread across laptops, ELNs, and ad‑hoc spreadsheets, with no owner
No clarity on what’s being captured, at what resolution, with what QC
AI/ML buzzwords with no one who has actually productionised data pipelines or models in biology
4. Early Regulatory / Quality Voice (Often Fractional)
What VCs want to see
Evidence that someone who has been through it before has looked at your plan
A development path that reads as realistic:
Right non‑clinical models
Appropriate endpoints
Sensible sequencing of tox, CMC, clinical, or validation work
Design of early experiments with an eye to future filings or partner diligence:
Documentation and data formats that won’t need total overhaul
Awareness of what’s “nice to have” vs required for an IND/CTA, CLIA, IVDR, etc.
A clear sense of when RA/QA becomes a full‑time need vs continuing fractional support
What worries them
“We’ll figure out regulatory later; right now it’s about the science”
Overly aggressive timelines to the clinic or to a regulated product
Fundamental misunderstanding of key regulatory hurdles in your modality
No sign that anyone is thinking about documentation, traceability, or validation
5. Business / Fundraising Partner
What VCs want to see
A science‑literate person who can run point on:
Fundraising narrative and process
Early BD and partnerships
Investor and partner follow‑through
A crisp articulation of “why us, why now, why this wedge into the market?”
A concrete financing and partnering roadmap:
How much you’re raising
What you’ll achieve with it
What that sets up in terms of options (Series A/B, strategic deals, etc.)
Recognition of the difference between “coffee chats” and structured processes
What worries them
Technically brilliant founders with no evident storytelling or deal capability
Over‑reliance on investors or advisors to “handle the business side”
No pipeline of future investors or partners—everything is reactive
Confusion between a finance function (CFO/controller) and a business‑building function (narrative, strategy, BD)
Artifacts Founders Can Bring to a Pitch to De‑Risk the Team
You may not have all five roles fully built out yet. That’s normal.
What matters is that you:
Understand the archetypes
Can show how they’re being covered today (full‑time, fractional, advisor)
Have a clear plan to fill the gaps with this round of capital
Here are concrete artifacts that make VCs feel that confidence.
1. Org Map + 18–24 Month Hiring Plan
A one‑page org showing:
Who’s in seat now
Which of the 5 archetypes they map to
Where you’re using fractional/advisory support
A forward‑looking hiring plan:
The next 3–5 critical hires
Timing (linked to milestones and runway)
Rough seniority and cost brackets
Bonus: explicitly tie each future hire to a platform or product milestone.
2. Example Scorecards for the Next 1–2 Key Hires
Pick one or two roles you haven’t filled yet (e.g., Biology↔Data Lead, Glue Operator, BD Partner) and bring:
A one‑page scorecard:
Must‑have experiences and skills
Success metrics for their first 12–18 months
A few example interview questions or case prompts
A note on how you’re sourcing and assessing candidates (internal network, retained search, etc.)
This does two things for investors:
Shows you’re deliberate about talent, not opportunistic
Signals you’ll be a good steward of their introductions and networks
3. Evidence of RA/QA and BD Thinking (Even if Fractional)
You don’t need a full‑time RA/QA head or CBO on day one. You do need to show the muscle exists.
Tangible signals:
A short memo or slide from your RA/QA advisor:
Key regulatory assumptions and timelines
Major risks and mitigations
A simple Gantt‑style view of development activities with regulatory “gates” marked
A basic BD/fundraising map:
Target investor/partner profiles
Your current relationships
How you plan to engage them over the next 12–18 months
Even a light version of this reassures VCs that you’re building with the end in mind, not improvising later.
Putting It All Together
When a VC is deciding whether to lead or pass on a platform biotech, they’re not just asking:
“Is the science exciting?”
They’re also asking:
“Do I believe this team can turn it into a real platform?”
“Will they choose the right first shots on goal?”
“Can they keep telling the story and raising capital as the bar goes up?”
Your first five hires—the Platform Architect, Glue Operator, Biology↔Data Lead, RA/QA voice, and Business/Fundraising Partner—are the lenses through which investors answer those questions.
If you can walk into a pitch and clearly show:
Who covers each archetype today
How they work together to build a platform engine
How you’ll evolve the team with this round of capital
…you move from “interesting science” to “credible platform company” in the eyes of investors.
How a Talent Partner Can Help
If you’re a founder or VC:
I can help you map these 5 roles onto your specific platform and modality
Define profiles, scorecards, and realistic comp for each hire
Decide where to go full-time vs fractional, and in what order
Used well, this sequence keeps your company focused on the two things that matter most in the first 18 months: building a real platform, and staying funded long enough to prove it.
References
Miguel Soares Brás – “The first 5 hires in a biotech startup will make or break your company.” LinkedIn, 2024.
Christian Rados – “First 5 hires every biotech needs.” LinkedIn, 2024.
BEC Search – “Life Sciences Startup: Foundational Hires for Biotech and Pharma.” BEC Search blog.
Aspire Life Sciences Search – “Hiring for platform biotechs.” Life Science Lens series, LinkedIn.
Biotech United – “Hiring Smart: A Biotech Startup’s Guide to Building the Right Team From Day One.” Biotech United blog.
Due.com – “The First 5 Hires That Make or Break Your Startup.”
Comments